The structural and functional connectome across Alzheimer's disease subtypes

阿尔茨海默病亚型的结构和功能连接组

• 批准号: 8969574
• 负责人: JOHN M RINGMAN
• 金额: $ 70.41万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-30 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8969574
• 关键词: APP gene; Adopted; Affect; Age; Alleles; Alzheimer' s Disease; Cerebrum; Characteristics; Clinical; Clinical Pathways; Databases; Dementia; Deposition; Disease; Etiology; Failure; Future; Genes; Genetic; Genotype; Human; Image; Impairment; Intervention; Late Onset Alzheimer Disease; Latino; Length; Ligands; Light; Magnetic Resonance Imaging; Measures; Mexican; Motor Pathways; Mutation; Nerve Degeneration; Neural Pathways; Neuraxis; Neurofibrillary Tangles; Pathologic Processes; Pathology; Pathway interactions; Perfusion; Persons; Phenotype; Population; Positron-Emission Tomography; Protocols documentation; Research; Risk; Spastic Paraparesis; Spin Labels; Synapses; Testing; Time; Transcranial magnetic stimulation; autosomal dominant mutation; base; clinical phenotype; disorder subtype; insight; neurophysiology; novel; presenilin-1; public health relevance; tau Proteins; white matter

 DESCRIPTION (provided by applicant): It is now clear that Alzheimer's disease is not a unitary phenomenon and that it can be divided into subtypes by their genetic origins, each of which may have distinct pathogenetic cascades and therefore may respond differentially to treatments. The Human Connectome Project (HCP) protocol provides the unique opportunity to comprehensively characterize imaging and clinical phenotypes of these AD subtypes. By applying the HCP protocol to persons at-risk for fully-penetrant autosomal dominant AD (ADAD due to either the A431E PSEN1 or V717I APP mutations) in conjunction with positron emission tomography (PET) imaging of tau using the novel ligand 18F-T807, we will be able to test the hypothesis that tau pathology spreads in a trans-synaptic manner along definable neural pathways. Applying the HCP protocol to this unique population will provide the opportunity to test the hypothesis of transynaptic spread of tau in the etiology of AD and provide the opportunity to differentiate pathological processes in subtypes of AD and therefore inform approaches to treatment. As PSEN1-related AD can present with spastic paraparesis, an easily assessed phenotype, we will be able to relate the neurophysiological parameters of central nervous system conduction time to connectivity measures in the HCP, helping to understand this characteristic and also validating HCP measures. We propose the following specific aims: 1) Perform network analyses relating the sequence of cortical deposition of neurofibrillary tangles measured using tau PET to white matter pathways and clinical status. 2) Identify connectomic (structural, functional, and connectional) and cerebral perfusion (ASL) MRI differences during neurodegeneration due to autosomal dominant AD mutations (ADAD due to specific mutations in the PSEN1 and APP genes) potentially revealing diverse pathological phenotypes. 3) Identify connectomic and cerebral perfusion MRI differences between AD of early (due to PSEN1 and APP mutations) and late onset (LOAD, associated or not with the APOE e4 allele). 4) Identify the connectomic bases for changes in central conduction times in motor pathways in ADAD and LOAD using TMS. This study will leverage the relatedness among persons with the A431E PSEN1 and V717I APP mutations to estimate mutation-associated variability in the connectome MRI. It will also provide the opportunity to explore variability of te connectome associated with Mexican Mestizo origin, a population typically under-represented in Alzheimer's and other neuroscientific research. Finally, by adopting the HCP phenotyping protocol into Spanish and applying it in this population, we will create a database to enable additional future studies in Latinos, a growing segment of the U.S. population.